- Home
- HOWL
as 11-05-2025 4:00pm EST
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 64.5M | IPO Year: | 2021 |
| Target Price: | $7.20 | AVG Volume (30 days): | 891.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.59 - $2.52 | Next Earning Date: | 11-04-2025 |
| Revenue: | N/A | Revenue Growth: | -90.55% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Werewolf Therapeutics Inc. (HOWL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| EVNIN LUKE | HOWL | Director | Nov 3 '25 | Sell | $1.29 | 60,369 | $77,876.01 | 3,943,359 | |
| MPM BioVentures 2014, L.P. | HOWL | 10% Owner | Nov 3 '25 | Sell | $1.29 | 94,063 | $121,341.27 | 6,147,610 | |
| GADICKE ANSBERT | HOWL | 10% Owner | Nov 3 '25 | Sell | $1.29 | 94,063 | $121,341.27 | 6,147,610 | |
| EVNIN LUKE | HOWL | Director | Oct 31 '25 | Sell | $1.28 | 73,192 | $93,685.76 | 3,943,359 | |
| MPM BioVentures 2014, L.P. | HOWL | 10% Owner | Oct 31 '25 | Sell | $1.28 | 114,044 | $145,976.32 | 6,147,610 | |
| GADICKE ANSBERT | HOWL | 10% Owner | Oct 31 '25 | Sell | $1.28 | 114,044 | $145,976.32 | 6,147,610 | |
| EVNIN LUKE | HOWL | Director | Oct 30 '25 | Sell | $1.43 | 55,795 | $79,786.85 | 3,943,359 | |
| MPM BioVentures 2014, L.P. | HOWL | 10% Owner | Oct 30 '25 | Sell | $1.43 | 86,936 | $124,318.48 | 6,147,610 | |
| GADICKE ANSBERT | HOWL | 10% Owner | Oct 30 '25 | Sell | $1.43 | 86,936 | $124,318.48 | 6,147,610 | |
| EVNIN LUKE | HOWL | Director | Oct 29 '25 | Sell | $1.55 | 86,154 | $133,538.70 | 3,943,359 |
Latest Werewolf Therapeutics Inc. News
HOWL Breaking Stock News: Dive into HOWL Ticker-Specific Updates for Smart Investing
MT Newswires
13 hours ago
Wedbush Halves Price Target on Werewolf Therapeutics to $3 From $6, Keeps Outperform Rating
GlobeNewswire
2 days ago
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Zacks
6 days ago
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
Zacks
7 days ago
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
Zacks
8 days ago
BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy
Zacks
13 days ago
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
Zacks
13 days ago
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
MT Newswires
a month ago
Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation
Compare HOWL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HOWL Werewolf Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.